Fig. 1

Pharmacogenomic analyses of gynecologic malignancies. a Schematic representation of pharmacogenomic analyses in gynecologic tumor-derived PDCs. Genomic and transcriptomics data were analyzed to identify single nucleotide variations and small indels and gene expression profiles. Short-term cultured PDCs were subjected to drug sensitivity screening against 37 molecular targeted compounds. b Mutational landscape of gynecologic tumors including ovarian cancer, endometrial cancer, cervical cancer, and uterine sarcoma. All mutations with an allele frequency of > 5% and depth of > 20 reads are shown. c Three-dimensional bubble plot demonstrating the frequency of non-synonymous cancer-driver mutations exclusively in tissue (black, left axis), PDC (blue, right axis), or shared between the two (gray, upper axis) (upper panel). The position of each dot or mutation is located on the quadrant based on its shared or private rate between primary tumor tissues and matched PDCs, and the distance reflects the number of cases that harbor respective mutation. Comparison of mRNA expression profiles between tumor tissue specimens and matched PDCs (bottom panel). Pearson’s correlation between tissue and PDCs is demonstrated as a heatmap